Identifying Novel Immunotherapy Targets Using Human-Relevant Tumour Models

• Leveraging patient-derived tumour systems to identify and validate novel targets across both tumour and immune cell populations
• Understanding how human-relevant screening approaches can uncover therapeutic opportunities missed by conventional preclinical models
• Evaluating the translational relevance of novel immunotherapy targets and therapeutic strategies in tumours resistant to first-generation checkpoint inhibitors

Speakers:

Alan Barge

Chief Executive Officer

4C Biomed